Resultats de la cerca - Justin P.O. Lindemann

  • Mostrar 1 - 17 resultats de 17
Refinar resultats
  1. 1
    A Good Drug Made Better: The Fulvestrant Dose-Response Story

    A Good Drug Made Better: The Fulvestrant Dose-Response Story per J.F.R. Robertson, Justin P.O. Lindemann, Sally Garnett, Elizabeth J. Anderson, Robert I. Nicholson, Irene Kuter, Julia M.W. Gee

    Publicat 2014
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  2. 2
    Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study

    Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study per J.F.R. Robertson, Antonio Llombart‐Cussac, Janusz Rolski, David Feltl, John Dewar, Euan Macpherson, Justin P.O. Lindemann, Matthew J. Ellis

    Publicat 2009
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  3. 3
    Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363

    Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363 per Michael Weller, Patrick Roth, Felix Sahm, Isabel Burghardt, Bernhard Schuknecht, Elisabeth J. Rushing, Luca Regli, Justin P.O. Lindemann, Andreas von Deimling

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors

    Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors per Kenji Tamura, Jun Hashimoto, Yuko Tanabe, Makoto Kodaira, Kan Yonemori, Takashi Seto, Fumihiko Hirai, Shuji Arita, Gouji Toyokawa, Lan Chen, Hiroshi Yamamoto, Toshio Kawata, Justin P.O. Lindemann, Taito Esaki

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer

    A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer per Erika Hamilton, Manish R. Patel, Anne Armstrong, Richard D. Baird, Komal Jhaveri, Matthias Hoch, Teresa Klinowska, Justin P.O. Lindemann, Shethah Morgan, Gaia Schiavon, Hazel M. Weir, Seock‐Ah Im

    Publicat 2018
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology

    Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology per Sally Garnett, Miguel Martín, Guy Jérusalem, Luboš Petruželka, Roberto Torres, Igor Bondarenko, Р. Ш. Хасанов, Didier Verhoeven, José Luiz Pedrini, I N Smirnova, Mikhail Lichinitser, Kelly Pendergrass, Justin P.O. Lindemann, Angelo Di Leo

    Publicat 2013
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

    Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer per Angelo Di Leo, Guy Jérusalem, Luboš Petruželka, Roberto Torres, Igor Bondarenko, Р. Ш. Хасанов, Didier Verhoeven, José Luiz Pedrini, И А Смирнова, Mikhail Lichinitser, Kelly Pendergrass, Sally Garnett, Justin P.O. Lindemann, Francisco Sapunar, Miguel Martín

    Publicat 2010
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer

    Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer per Neill Patani, Anita K. Dunbier, H Anderson, Zara Ghazoui, Ricardo Ribas, Elizabeth J. Anderson, Qiong Gao, Roger A’Hern, Alan Mackay, Justin P.O. Lindemann, Robert Wellings, Jill Walker, Irene Kuter, Lesley‐Ann Martin, Mitch Dowsett

    Publicat 2014
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results

    A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy re... per E. Hamilton, M. Oliveira, Nicholas C. Turner, J. García-Corbacho, Cristina Hernándo, Eva Ciruelos, Peter Kabos, Manuel Ruíz‐Borrego, Anne Armstrong, Mehul Patel, Christos Vaklavas, Chris Twelves, Valentina Boni, Jason Incorvati, Tim Brier, L. Gibbons, Teresa Klinowska, Justin P.O. Lindemann, Christopher J. Morrow, Anne-Marie Sykes, Richard D. Baird

    Publicat 2024
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population

    BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrog... per Nicholas C. Turner, Ashley E. Alarcon-Rozas, Anne Armstrong, M. Philco, Yamil Alonso Lopez Chuken, Marie‐Paule Sablin, Kenji Tamura, Armando Villanueva, José Alejandro Pérez Fidalgo, S.Y. Amy Cheung, Claire Corcoran, Marie Cullberg, Barry R. Davies, Elza C. de Bruin, Andrew Foxley, Justin P.O. Lindemann, Rhiannon Maudsley, Michele Moschetta, E. Outhwaite, Martin Pass, Paul Rugman, Gaia Schiavon, Mafalda Oliveira

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial

    Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial per Costanza Paoletti, Gaia Schiavon, Emily M. Dolce, Elizabeth P. Darga, T. Hedley Carr, Joseph Geradts, Matthias Hoch, Teresa Klinowska, Justin P.O. Lindemann, Gayle Marshall, Shethah Morgan, Parul Patel, Vicky Rowlands, Nitharsan Sathiyayogan, Kimberly Aung, Erika Hamilton, Manish R. Patel, Anne Armstrong, Komal Jhaveri, Seock‐Ah Im, Nadia Iqbal, Fouziah Butt, Caroline Dive, Elizabeth A. Harrington, J. Carl Barrett, Richard D. Baird, Daniel F. Hayes

    Publicat 2018
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2− Primary Breast Cancer

    A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diag... per J.F.R. Robertson, Abigail Evans, Stephan Henschen, Cliona C. Kirwan, Ali Jahan, Laura Kenny, J. Michael Dixon, Peter Schmid, Ashutosh Kothari, Omar Mohamed, Peter A. Fasching, Kwok‐Leung Cheung, Rachel Wuerstlein, Danielle Carroll, Teresa Klinowska, Justin P.O. Lindemann, Alexander MacDonald, Richard Mather, Rhiannon Maudsley, Michele Moschetta, Myria Nikolaou, Martine P. Roudier, Tinnu Sarvotham, Gaia Schiavon, Diansong Zhou, Li Zhou, Nadia Harbeck

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with<i>AKT1</i>E17K-Mutant, ER-Positive Metastatic Breast Cancer

    Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with<i>AKT1</i>E17K-Mutant, ER-Positive Metastatic Breast Cancer per Lillian M. Smyth, Kenji Tamura, Mafalda Oliveira, Eva Ciruelos, Ingrid A. Mayer, Marie‐Paule Sablin, Laura Biganzoli, Helen J. Ambrose, Jack Ashton, Alan Barnicle, Des D. Cashell, Claire Corcoran, Elza C. de Bruin, Andrew Foxley, Joana Hauser, Justin P.O. Lindemann, Rhiannon Maudsley, Robert McEwen, Michele Moschetta, Martin Pass, Vicky Rowlands, Gaia Schiavon, Udai Banerji, Maurizio Scaltriti, Barry S. Taylor, Sarat Chandarlapaty, José Baselga, David M. Hyman

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <i>PIK3CA</i>-Mutated Breast and Gynecologic Cancers

    A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <i>PIK3CA</i>-Mutated Breast and Gynecologic Cancers per Udai Banerji, Emma Dean, José Alejandro Pérez Fidalgo, Gerald Batist, Philippe L. Bédard, Benoît You, Shannon N. Westin, Peter Kabos, Michelle D. Garrett, Mathew Tall, Helen Ambrose, J. Carl Barrett, T. Hedley Carr, S.Y. Amy Cheung, Claire Corcoran, Marie Cullberg, Barry R. Davies, Elza C. de Bruin, Paul Elvin, Andrew Foxley, Peter Lawrence, Justin P.O. Lindemann, Rhiannon Maudsley, Martin Pass, Vicky Rowlands, Paul Rugman, Gaia Schiavon, James Yates, Jan H.M. Schellens

    Publicat 2017
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    AKT Inhibition in Solid Tumors With <i>AKT1</i> Mutations

    AKT Inhibition in Solid Tumors With <i>AKT1</i> Mutations per David M. Hyman, Lillian M. Smyth, Mark T.A. Donoghue, Shannon N. Westin, Philippe L. Bédard, Emma Dean, Hideaki Bando, Anthony B. El-Khoueiry, José Alejandro Pérez Fidalgo, Alain C. Mita, Jan H.M. Schellens, Matthew T. Chang, Jonathan Reichel, Nancy Bouvier, S. Duygu Selçuklu, Tara E. Soumerai, Jean Torrisi, Joseph P. Erinjeri, Helen Ambrose, J. Carl Barrett, Brian Dougherty, Andrew Foxley, Justin P.O. Lindemann, Robert McEwen, Martin Pass, Gaia Schiavon, Michael F. Berger, Sarat Chandarlapaty, David B. Solit, Udai Banerji, José Baselga, Barry S. Taylor

    Publicat 2017
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non–<i>BRCA1/2</i>-Mutant Cancers

    Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non–<i>BRCA1/2</i>-Mutant Cancers per Timothy A. Yap, Rebecca Kristeleit, Vasiliki Michalarea, Stephen J. Pettitt, Joline S.J. Lim, Suzanne Carreira, Desamparados Roda, Rowan Miller, Ruth Riisnaes, Susana Miranda, Ines Figueiredo, Daniel Nava Rodrigues, Sarah Ward, Ruth Matthews, Mona Parmar, Alison Turner, Nina Tunariu, Neha Chopra, Heidrun Gevensleben, Nicholas C. Turner, Ruth Ruddle, Florence I. Raynaud, Shaun Decordova, Karen E. Swales, Laura Finneran, Emma Hall, Paul Rugman, Justin P.O. Lindemann, Andrew Foxley, Christopher J. Lord, Udai Banerji, Ruth Plummer, Bristi Basu, Juanita Lopez, Yvette Drew, Johann S. de Bono

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

    The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance per Mandy Lawson, Natalie Cureton, Susana R�os, Azadeh Cheraghchi-Bashi, Jelena Urosevic, Sophie D’Arcy, Oona Delpuech, Michelle DuPont, David I. Fisher, Eric T. Gangl, Hilary Lewis, Dawn Trueman, Neha Wali, Stuart C. Williamson, Jennifer Moss, Élodie Montaudon, Héloïse Derrien, Elisabetta Marangoni, Ricardo J. Miragaia, Sladjana Gagrica, Pablo Morentin Gutierrez, Thomas A. Moss, Gareth Maglennon, Daniel Sutton, Radosław Polański, Alan Rosen, Jonathan Cairns, Pei Zhang, Mònica Sánchez-Guixé, Violeta Serra, Susan E. Critchlow, James S. Scott, Justin P.O. Lindemann, Simon T. Barry, Teresa Klinowska, Christopher J. Morrow, Larissa S. Carnevalli

    Publicat 2023
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: